A214610 Stock Overview
Provides on-site diagnostic systems based on Lab-on-a-Chip technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MiCo BioMed Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,890.00 |
| 52 Week High | ₩33,100.00 |
| 52 Week Low | ₩4,500.00 |
| Beta | 0 |
| 1 Month Change | -2.78% |
| 3 Month Change | -65.07% |
| 1 Year Change | -69.55% |
| 3 Year Change | -92.37% |
| 5 Year Change | -93.84% |
| Change since IPO | -94.38% |
Recent News & Updates
Shareholder Returns
| A214610 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 3.8% | 10.1% | 6.9% |
| 1Y | -69.6% | -20.2% | -7.7% |
Return vs Industry: A214610 underperformed the KR Medical Equipment industry which returned -20.8% over the past year.
Return vs Market: A214610 underperformed the KR Market which returned -7.2% over the past year.
Price Volatility
| A214610 volatility | |
|---|---|
| A214610 Average Weekly Movement | 13.8% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A214610's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A214610's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 71 | Min Young Jeong | www.micobiomed.com |
MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system.
MiCo BioMed Co., Ltd. Fundamentals Summary
| A214610 fundamental statistics | |
|---|---|
| Market cap | ₩25.18b |
| Earnings (TTM) | -₩27.15b |
| Revenue (TTM) | ₩4.64b |
5.4x
P/S Ratio-0.9x
P/E RatioIs A214610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214610 income statement (TTM) | |
|---|---|
| Revenue | ₩4.64b |
| Cost of Revenue | ₩10.66b |
| Gross Profit | -₩6.02b |
| Other Expenses | ₩21.13b |
| Earnings | -₩27.15b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.27k |
| Gross Margin | -129.73% |
| Net Profit Margin | -585.01% |
| Debt/Equity Ratio | 70.2% |
How did A214610 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 11:01 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiCo BioMed Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.